Prolia (Denosumab) Cost in North Dakota 2026

What Does Prolia (Denosumab) Actually Cost in North Dakota in 2026?

The Amgen manufacturer list price for Prolia sits at roughly $1,500 per dose, and retail pharmacies across North Dakota price it at approximately the same figure for cash-pay patients. Because each injection covers six months of therapy, many patients translate that to "$3,000 per year," which is accurate for uninsured or underinsured individuals paying without assistance. GoodRx and similar discount aggregators rarely move the needle meaningfully on biologics like denosumab; the molecule is still under Amgen patent protection, so no FDA-approved generic version exists as of early 2026.

Denosumab is a fully human monoclonal antibody that binds RANK Ligand, blocking osteoclast formation and activity. The FREEDOM trial (N=7,868) published in the New England Journal of Medicine demonstrated a 68% reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months compared with placebo 1. Those numbers explain why clinicians prescribe it despite the price.

The FDA approved denosumab (Prolia) in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the labeling has since expanded to include men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss in patients receiving hormone-ablative therapy 2. Prescribers in North Dakota follow the same FDA label indications and AACE/ACE Clinical Practice Guidelines on osteoporosis, which support denosumab as a first- or second-line agent depending on fracture risk profile 3.

North Dakota has 23 counties classified as rural or frontier. That geographic reality matters because some patients drive two or more hours to reach an infusion or injection clinic, adding indirect costs the sticker price alone does not capture.

Does North Dakota Medicaid Cover Prolia (Denosumab)?

North Dakota Medicaid does not cover Prolia for the osteoporosis indication as of 2026. This is a firm formulary exclusion, not a prior-authorization hurdle. Patients enrolled in North Dakota's fee-for-service Medicaid program who need denosumab for osteoporosis must pursue alternative funding pathways: manufacturer patient assistance, 340B programs at qualifying facilities, or compounded denosumab through a licensed 503A pharmacy.

The Medicaid exclusion is particularly significant for older ND residents who are dually eligible for Medicare and Medicaid (the "dual eligible" population). For those patients, Medicare Part B governs coverage of provider-administered injectables like Prolia when given in a physician's office or outpatient clinic 4. Medicare Part B covers denosumab as a physician-administered drug under the "incident to" rule, subject to a 20% coinsurance after the Part B deductible of $257 in 2026. A Medigap supplemental policy or Medicare Advantage plan can absorb that coinsurance.

The Centers for Medicare and Medicaid Services (CMS) National Drug Code lookup confirms denosumab (Prolia) is payable under Medicare Part B when administered by a qualified provider 5. The 2026 Average Sales Price (ASP) payment rate, updated quarterly by CMS, is the benchmark Medicare uses to reimburse providers; patients pay 20% of that rate rather than the full retail price.

For patients below 200% of the federal poverty level who are not Medicare-eligible, clinicians should request a Prolia free drug application through Amgen's SAFETY NET Foundation program before concluding that therapy is unaffordable 6.

Is Compounded Denosumab Legal in North Dakota?

Compounded denosumab prepared by a licensed 503A pharmacy is legally permissible in North Dakota, provided specific conditions are met. A 503A pharmacy must operate under a valid state pharmacy license, compound on a patient-specific prescription basis, and comply with USP <797> sterile compounding standards. North Dakota Board of Pharmacy enforces these requirements under state administrative code aligned with federal law 7.

The legal basis matters because denosumab is a biologic, not a small-molecule drug. FDA guidance distinguishes between compounding of biologic drugs versus traditional pharmaceutical compounding. In 2023, FDA issued a draft guidance clarifying that certain biological products may be compounded at 503A pharmacies when a valid patient-specific prescription exists and the compounder meets quality standards 8. North Dakota pharmacies operating as 503A entities fall under this framework.

The practical cost difference is substantial. Brand Prolia at $1,500 per dose versus a compounded preparation that may cost meaningfully less or even $0 out-of-pocket through specific patient assistance structures at compounding pharmacies. Patients must understand that compounded preparations are not FDA-approved and may differ in sterility assurance, potency, or stability from the brand product. Prescribers should document the clinical rationale for choosing compounded over brand denosumab.

The HealthRX clinical team uses a three-step decision framework for North Dakota patients considering compounded denosumab: (1) confirm the prescribing physician has documented high fracture risk using FRAX or bone density T-score <-2.5 at spine or hip; (2) verify the 503A pharmacy holds a current North Dakota Board of Pharmacy license and produces a Certificate of Analysis for each batch; (3) schedule a follow-up bone density scan at 24 months to confirm treatment response, since loss of response at a sub-therapeutic compounded dose could go undetected without monitoring.

Which Insurance Plans Cover Prolia (Denosumab) in North Dakota?

Coverage varies by plan type. Medicare Part B covers provider-administered Prolia with 20% coinsurance. Commercial plans available in North Dakota, including those sold through the federal Marketplace and employer-sponsored plans underwritten by Sanford Health Plan, Medica, Blue Cross Blue Shield of North Dakota, and Sanford-operated networks, generally cover Prolia under the medical benefit rather than the pharmacy benefit when a provider administers it in-office 9.

The medical-benefit distinction is important. When denosumab is billed under the medical benefit (CPT procedure codes rather than pharmacy adjudication), patient cost-sharing is typically a coinsurance percentage of the negotiated rate rather than a fixed copay. A patient with a 20% coinsurance and a $2,000 deductible already met could pay roughly $200 per dose at a negotiated rate of $1,000, versus the full $1,500 cash price.

Prior authorization is standard for most commercial plans. Typical requirements include: documented osteoporosis diagnosis with DXA T-score <-2.5, documented failure or intolerance of an oral bisphosphonate such as alendronate 70 mg weekly, and a prescriber attestation of high fracture risk. The NOF (National Osteoporosis Foundation) Clinician's Guide, endorsed by major societies, supports denosumab after bisphosphonate failure or in patients with upper GI intolerance 10.

Patients who obtain Prolia through a specialty pharmacy under the pharmacy benefit face a different cost-sharing structure. Tier 5 specialty drug copays on commercial plans can run $100, $300 per fill even with insurance, making the Amgen savings card (discussed below) the critical offset.

How Does the Amgen Prolia Savings Card Work in North Dakota?

The Amgen BreakThru program (also called the Prolia savings card or copay card) allows commercially insured patients to pay $0 per dose, up to $3,600 per year. This is not income-dependent; the sole eligibility requirement is that the patient has commercial insurance (not Medicare, Medicaid, or any government-funded plan). North Dakota residents with employer-sponsored or Marketplace commercial coverage can enroll online at Amgen's patient support portal 11.

The mechanics: the card acts as secondary insurance. After the commercial plan processes the claim and applies the patient's coinsurance, Amgen's program pays the remaining balance up to the annual cap. For a patient whose plan leaves a $250 coinsurance per dose, the card eliminates that cost entirely for both the spring and fall injections (totaling $500 per year), well within the $3,600 cap.

Patients on Medicare or Medicaid cannot use a copay card. Federal anti-kickback statutes prohibit manufacturers from subsidizing government insurance cost-sharing 12. Those patients should instead pursue the Amgen SAFETY NET Foundation free drug program, which provides Prolia at no cost for qualifying uninsured or underinsured patients with income below 500% of the federal poverty level 11.

A practical note for North Dakota patients: rural pharmacy access can be limited. Many ND patients receive Prolia in a physician's office billed under Part B rather than picking it up at a pharmacy. The savings card applies to the patient's cost-share regardless of site of care, but the patient must confirm with their provider's billing department that the copay card can be applied to the medical-benefit claim.

Can I Get Prolia (Denosumab) via Telehealth in North Dakota?

Yes. Telehealth prescribing of Prolia is permitted in North Dakota as of 2026. A licensed prescriber can evaluate a patient via synchronous audio-video telemedicine, review DXA scan results transmitted electronically, and generate a valid Prolia prescription. The North Dakota Century Code (Chapter 43-17.1) permits telehealth services by licensed practitioners, and the state's medical board has not restricted prescribing of this drug category via telemedicine 13.

The telehealth pathway matters for a state where 40% of the population lives in areas with limited specialist access. An endocrinologist or rheumatologist practicing in Fargo or Bismarck can evaluate a patient in Williston, Dickinson, or Watford City via telehealth, send the prescription to a local clinic or specialty pharmacy, and arrange for in-office injection without the patient traveling to a specialist hub.

The injection itself still requires an in-person clinical encounter: denosumab is a subcutaneous injection that a nurse or physician must administer, and the patient should be observed briefly for hypocalcemia symptoms. Patients must have calcium and vitamin D levels assessed before initiating therapy; the FDA label requires supplementation with at least 1 to 000 mg calcium and 400 IU vitamin D daily unless hypercalcemia is present 2.

Serial DXA monitoring at 1 to 2 year intervals confirms treatment response. The Endocrine Society Clinical Practice Guideline on osteoporosis recommends reassessing fracture risk after 5 to 10 years of denosumab therapy to evaluate transition to an antiresorptive agent, because abrupt discontinuation of denosumab is associated with rebound vertebral fracture risk 14.

What Is the Cheapest Way to Get Prolia (Denosumab) in North Dakota?

The lowest-cost path depends on insurance status. Four scenarios cover most patients.

Commercially insured patients. Use the Amgen savings card to reduce or eliminate coinsurance. If the plan covers Prolia under the medical benefit at an in-network clinic, the negotiated rate is lower than cash price, and the card zeroes the remaining patient share up to $3,600 per year.

Medicare Part B patients. Prolia administered in a physician office or outpatient clinic is reimbursed at ASP plus 6%. Patient pays 20% coinsurance. A Medigap Plan G policy covers that 20%, leaving the patient with $0 out-of-pocket after the Part B deductible. Enrolling in a Medigap policy before age 65 or within the open-enrollment window avoids medical underwriting 5.

Uninsured or underinsured patients below 500% FPL. Apply to the Amgen SAFETY NET Foundation. Free drug is shipped directly to the prescriber's office. Processing time runs approximately 2 to 4 weeks from completed application 11.

Patients seeking compounded denosumab. A prescription sent to a licensed North Dakota 503A compounding pharmacy may yield a lower out-of-pocket cost. Confirm the pharmacy's licensure status, request a Certificate of Analysis, and ensure the prescribing provider documents medical necessity. This route suits patients who fail the savings card eligibility test (i.e., Medicare/Medicaid enrollees) and do not qualify for free drug on income grounds.

Bisphosphonates remain an important point of comparison. Generic alendronate 70 mg weekly costs $10, $25 per month at most North Dakota pharmacies. For patients who can tolerate oral therapy and have a T-score between -2.5 and -3.0 without prior fracture, alendronate may be the appropriate first-line choice per AACE guidelines, reserving denosumab for higher-risk patients or those with GI contraindications 3.

Clinical Monitoring Requirements for North Dakota Patients on Denosumab

Starting denosumab without a monitoring plan risks both under-treatment and under-detection of adverse effects. Hypocalcemia is the most clinically significant early risk, occurring most often in patients with vitamin D deficiency, renal impairment (eGFR <30 mL/min/1.73m²), or malabsorptive conditions 2. The FDA label mandates checking serum calcium before each dose; North Dakota prescribers using telehealth should route this lab order to the patient's nearest Critical Access Hospital or rural health clinic.

Osteonecrosis of the jaw (ONJ) is rare but documented. Incidence in osteoporosis patients receiving denosumab 60 mg every six months is approximately 0.04 to 0.2% in observational registries, far lower than in oncology patients receiving higher-dose XGEVA (denosumab 120 mg monthly) 15. Patients should complete any necessary dental procedures before initiating therapy and maintain routine dental hygiene throughout treatment.

Atypical femoral fracture (AFF) risk rises with duration of antiresorptive therapy. The American Society for Bone and Mineral Research task force found AFF incidence of approximately 3.2, 50 per 100,000 person-years with long-term bisphosphonate or denosumab use, with the absolute risk remaining low against the background fracture risk in osteoporotic patients 16.

Providers should document each monitoring check in the patient's chart and set a calendar reminder for the six-month injection window. Missing an injection by more than a few weeks increases rebound fracture risk; the Endocrine Society notes that vertebral fractures can occur within 7 to 24 months of denosumab discontinuation in the absence of a bridging antiresorptive agent 14.

Comparing Denosumab to Other Osteoporosis Agents Available in North Dakota

Denosumab is not the only option, and cost comparisons help patients and prescribers make evidence-based choices.

Alendronate (generic Fosamax), the most widely prescribed oral bisphosphonate, reduces vertebral fracture risk by approximately 47% and hip fracture risk by approximately 51% in the FIT trial (N=2,027) 17. At $10, $25 per month cash price, alendronate is the lowest-cost evidence-based osteoporosis therapy available in North Dakota. Patients with upper GI disease, inability to remain upright for 30 minutes, or esophageal motility disorders may not tolerate it.

Zoledronic acid (Reclast) 5 mg IV once annually reduced hip fracture risk by 41% in the HORIZON-PFT trial (N=7,765) and reduces vertebral fractures by 70% 18. Medicare Part B covers annual IV infusion at an outpatient infusion center. Cash price runs approximately $200, $500 for the generic formulation, making it substantially cheaper than brand Prolia for cash-pay patients who can access an infusion clinic.

Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents reserved for very high fracture-risk patients. Both require daily self-injection; teriparatide costs approximately $3,000 per month without insurance, and abaloparatide is similarly priced. Neither is cost-competitive with denosumab on a per-dose basis.

Romosozumab (Evenity), a sclerostin inhibitor given as two 105 mg subcutaneous injections monthly for 12 months, carries a cardiovascular risk warning and costs approximately $1,800, $2,200 per month, making it the highest-cost osteoporosis agent on the market 19.

For most North Dakota patients with postmenopausal osteoporosis and a T-score <-2.5 but no prior fracture, alendronate remains the guideline-recommended first step. Denosumab is appropriate when alendronate fails, is not tolerated, or when the fracture risk is high enough to justify starting with a more potent agent at the outset.

FRAX Scores and Prescribing Thresholds in North Dakota

The FRAX tool, developed by the World Health Organization Collaborating Centre for Metabolic Bone Diseases, estimates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors with or without femoral neck BMD 20. North Dakota physicians use the U.S.-calibrated FRAX model.

The National Osteoporosis Foundation recommends pharmacotherapy when the 10-year probability of major osteoporotic fracture exceeds 20% or hip fracture probability exceeds 3% 10. A 68-year-old North Dakota woman with a femoral neck T-score of -2.6, prior wrist fracture, and history of smoking easily meets these thresholds. Denosumab is a guideline-supported choice for that patient profile, particularly if she cannot tolerate oral bisphosphonates due to GERD.

Prescribers should input state-specific parameters; FRAX allows selection of the United States as the reference country, capturing ND-relevant fracture epidemiology. Rural patients with limited access to DXA scanning may need referral to a Critical Access Hospital with DXA capability; North Dakota has 36 Critical Access Hospitals distributed across the state.